Gw Pharma ADR (GWPH) Stock Price, Quote, News and Overview
NASDAQ:GWPH - Nasdaq -
GWPH Quote, Performance and Key Statistics
218.96
-0.32 (-0.15%)
The current stock price of GWPH is 218.96 null. In the past month the price increased by 0.6%. In the past year, price increased by 101.96%.
About GWPH
Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.
Company Info
Gw Pharma ADR
SOVEREIGN HOUSE VISION PARK HISTON
CAMBRIDGE X0 CB24 9BZ
CEO: Justin Gover
Phone: 44-12-2326-6800
Gw Pharma ADR / GWPH FAQ
What is the stock price of Gw Pharma ADR today?
The current stock price of GWPH is 218.96 null. The price decreased by -0.15% in the last trading session.
What is the ticker symbol for Gw Pharma ADR stock?
The exchange symbol of Gw Pharma ADR is GWPH and it is listed on the Nasdaq exchange.
On which exchange is GWPH stock listed?
GWPH stock is listed on the Nasdaq exchange.
What is Gw Pharma ADR worth?
Gw Pharma ADR (GWPH) has a market capitalization of 6.86B null. This makes GWPH a Mid Cap stock.
What are the support and resistance levels for Gw Pharma ADR (GWPH) stock?
Gw Pharma ADR (GWPH) has a support level at 218.89 and a resistance level at 219.01. Check the full technical report for a detailed analysis of GWPH support and resistance levels.
Should I buy Gw Pharma ADR (GWPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GWPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GWPH, evaluating the profitability, health, valuation and growth aspects
- Gw Pharma ADR (GWPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Gw Pharma ADR (GWPH) Sales and EPS estimates to see what analysts future expectations are.
- Gw Pharma ADR (GWPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Gw Pharma ADR (GWPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- Gw Pharma ADR (GWPH) Stock Chart to make your own analysis
- Gw Pharma ADR (GWPH) Latest news and press-releases to stay up to date.
Does Gw Pharma ADR (GWPH) stock pay dividends?
GWPH does not pay a dividend.
When does Gw Pharma ADR (GWPH) report earnings?
Gw Pharma ADR (GWPH) will report earnings on 2022-02-18, before the market open.
What is the Price/Earnings (PE) ratio of Gw Pharma ADR (GWPH)?
Gw Pharma ADR (GWPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.86).
GWPH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GWPH. When comparing the yearly performance of all stocks, GWPH is one of the better performing stocks in the market, outperforming 76.48% of all stocks.
GWPH Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GWPH. Both the profitability and the financial health of GWPH get a neutral evaluation. Nothing too spectacular is happening here.
GWPH Financial Highlights
Over the last trailing twelve months GWPH reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS decreased by -675% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -12.49% | ||
| ROA | -7.47% | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |
GWPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 64% to GWPH. The Buy consensus is the average rating of analysts ratings from 9 analysts.